title: Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study.
authors.affiliation: Hematology Department, CHU Hotel-Dieu, Nantes patrice.chevallier@chu-nantes.fr.
authors.forename: Patrice
authors.initials: P
authors.lastname: Chevallier
authors.affiliation: Hematology Department, CHU, Toulouse.
authors.forename: Francoise
authors.initials: F
authors.lastname: Huguet
authors.affiliation: Hematology Department, Hôpital Saint-Louis, Paris.
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Raffoux
authors.affiliation: Hematology Department, Institut Paoli-Calmette, Marseille.
authors.forename: Anne
authors.initials: A
authors.lastname: Etienne
authors.affiliation: Hematology Department, CHU, Bordeaux.
authors.forename: Thibaut
authors.initials: T
authors.lastname: Leguay
authors.affiliation: Hematology Department, Hopital Saint-Antoine, Paris.
authors.forename: Francoise
authors.initials: F
authors.lastname: Isnard
authors.affiliation: Hematology/Biology Department, CHU Hotel-Dieu, Nantes, France.
authors.forename: Nelly
authors.initials: N
authors.lastname: Robillard
authors.affiliation: Hematology Department, CHU Hotel-Dieu, Nantes.
authors.forename: Thierry
authors.initials: T
authors.lastname: Guillaume
authors.affiliation: Hematology Department, CHU Hotel-Dieu, Nantes.
authors.forename: Jacques
authors.initials: J
authors.lastname: Delaunay
authors.affiliation: Hematology Department, Institut Paoli-Calmette, Marseille.
authors.forename: Aude
authors.initials: A
authors.lastname: Charbonnier
authors.affiliation: Hematology Department, CHU, Bordeaux.
authors.forename: Arnaud
authors.initials: A
authors.lastname: Pigneux
authors.affiliation: Hematology Department, CHU Hotel-Dieu, Nantes.
authors.forename: Pierre
authors.initials: P
authors.lastname: Peterlin
authors.affiliation: Hematology/Biology Department, CHU Hotel-Dieu, Nantes, France.
authors.forename: Marie C
authors.initials: MC
authors.lastname: Bené
authors.affiliation: Immunomedics, Inc., Morris Plains, NJ, USA.
authors.forename: William A
authors.initials: WA
authors.lastname: Wegener
authors.affiliation: Immunomedics, Inc., Morris Plains, NJ, USA.
authors.forename: David M
authors.initials: DM
authors.lastname: Goldenberg
authors.affiliation: Hematology Department, Hôpital Saint-Louis, Paris.
authors.forename: Hervé
authors.initials: H
authors.lastname: Dombret
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage; D006801:Humans; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D012008:Recurrence; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000378:metabolism; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D051918:Sialic Acid Binding Ig-like Lectin 2; C448700:epratuzumab; D014750:Vincristine; D003907:Dexamethasone
keywords: B-ALL; CD22; chemoimmunotherapy; epratuzumab; minimal residual disease; older patients; refractory; relapse